Today Royal Philips (NYSE: PHG, AEX: PHIA) announced the US launch of InnoSpire Go, Philips smallest and lightest portable hand-held nebulizer system designed to deliver medication in just four minutes, reducing treatment time by up to 25 percent.  The easy-to-use and virtually silent InnoSpire Go puts hospital-grade nebulizer technology into the hands of the user for portable, fast and effective medication delivery.
Globally, more than 252 million people suffer from asthma and another 251 million from chronic obstructive pulmonary disease (COPD). [2, 3] Though incurable, asthma and COPD can be made more manageable with the correct therapy, such as nebulized medications. The InnoSpire Go transforms needed medication into ultra-fine droplets, so that they can penetrate even the smallest structures of the lungs effectively. With a built-in, rechargeable battery that provides up to 30 treatments per charge, and simple two-part assembly, the InnoSpire Go can be used at home or on the go.
“We want to provide patients with respiratory diseases with a means of effective and rapid therapy,” said Linda Trevenen, Business Leader, Respiratory Drug Delivery at Philips. “InnoSpire Go daily inhalation therapy is as easy as brushing your teeth. Thanks to this nebulizer’s light weight, ease of use, and fast, four minute treatment time, it is ready for use anywhere, anytime, and is particularly suitable for children and individuals who want to maintain an active lifestyle.”
The clinically proven vibrating mesh technology inside InnoSpire Go, turns liquid medication into a fine mist, for fast treatment in four minutes with less wasted medication and no replaceable batteries.  Philips InnoSpire Go can be used with commonly prescribed drugs for respiratory disease. Aerosol performance is maintained over the life of the product and is delivered with audible and visible indicators that signal therapy completion. The easily detachable mouthpiece makes the InnoSpire Go easy to clean and maintain. Each InnoSpire Go includes our Lite Touch mask for optimal comfort.
InnoSpire Go is available in the United States and additional countries including Australia, Denmark, Finland, Germany, Norway, and the United Kingdom.
References 2.5 ml Salbutamol, 25 percent reduction versus predecessor Aeroneb Go  Global Burden of Disease Study, World Health Organization 2016  Global Asthma Network. 2014. Retrieved from: http://www.globalasthmareport.org  2.5 ml Salbutamol, less wasted medication than jet nebulizer technology. Typically 0.3 ml total residual volume.